Hormone & Organ Health

GHRH analogs are built to resemble growth-hormone-releasing hormone, the hypothalamic signal that tells the pituitary to release a pulse. Sermorelin, tesamorelin, and the CJC-1295 component all bind the GHRH receptor — in effect repeating a message the body already sends, with differences in stability and how long the signal persists.

Ipamorelin reaches the same pituitary cells through a different door. It is a selective growth hormone secretagogue, acting at the ghrelin receptor rather than the GHRH receptor — a second, parallel input to the same system. Selective is the operative word: research interest centers on its comparatively narrow action on that pathway.

Because the two mechanisms are separate, they are sometimes paired. CJC-1295 / ipamorelin and tesamorelin / ipamorelin combine an analog with the secretagogue; sermorelin and tesamorelin are also prescribed on their own.

Each compound has its own clinical questionnaire covering medical history, current medications, symptoms, and goals. A licensed provider reviews it and may request labs before deciding anything.

What follows is a judgement. The provider weighs your history against the current evidence, decides whether the axis is the right thing to address at all, and selects a compound and dose if it is. Some histories take this class off the table entirely, and the provider will say so. If treatment is appropriate, a licensed U.S. pharmacy compounds and ships it with instructions, and follow-up check-ins keep the plan under review.

If your questions are more about appetite, glucose, and body composition than the growth hormone axis, metabolic support and fat loss is the more relevant place to start.